Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01683-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Yi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Center, The Fourth People's Hospital of Shenyang, Shenyang, 223400, Liaoning Province, China. Hauptthemen laut MEDLINE: Zoledronic Acid, Osteoporosis, Bone Density Conservation Agents, Calcitriol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To investigate the effectiveness and safety of combining zoledronic acid with calcium supplements and calcitriol in treating primary osteoporosis in elderly patients. METHODS: Seventy-eight elderly patients with primary osteoporosis were recruited. They were randomly assigned in a 1:1 ratio to either the CC group (calcium carbonate D3 tablets + calcitriol soft capsules) or the CCZ group (calcium carbonate D3 tablets + calcitriol soft capsules + zoledronic acid injection). The treatment duration was 1 year. Bone mineral density (BMD), bone metabolism markers, quality of life (QoL), clinical efficacy, and incidence of adverse reactions (ARs) were assessed. RESULTS: CCZ group showed increased BMD in the lumbar spine (L1~L4 segments), femoral neck, and hip after treatment relative to CC group. Serum levels of bone-specific alkaline phosphatase, cross-linked type 1 collagen C-terminal peptide, and N-terminal propeptide of type 1 procollagen decreased, while osteocalcin levels increased. The QoL Questionnaire of the European Foundation for Osteoporosis scores decreased (P < 0.05 for all comparisons). The clinical effective rates were 76.93% in the CC group and 92.31% in the CCZ group, with AR rates of 23.08% and 12.82%, respectively (P < 0.05 for both). CONCLUSION: Zoledronic acid treatment in elderly patients with primary osteoporosis demonstrates significant efficacy by increasing bone density, improving bone metabolism, enhancing QoL, and exhibiting high safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatric Center, The Fourth People's Hospital of Shenyang, Shenyang, 223400, Liaoning Province, China.
- Department of Geriatrics, Lianshui County People's Hospital, Huai'an, 223400, Jiangsu Province, China.
- Department of Orthopedics, Spine Surgery, 907 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Nanping, 353000, Fujian Province, China. 13960614968@163.comom.
Zitieren
APA
Zhang, Y., Tian, Y., & Chen, X. (2025). Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01683-4
Vancouver
Zhang Y, Tian Y, Chen X. Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01683-4
BibTeX
@article{Zhang2025,
author = {Zhang, Yi and Tian, Yuan and Chen, Xiaojun},
title = {Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01683-4}
}
EUVIMED